SSA

Schonfeld Strategic Advisors Portfolio holdings

AUM $13.3B
1-Year Est. Return 26.83%
This Quarter Est. Return
1 Year Est. Return
+26.83%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$14.9B
AUM Growth
-$969M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
2,437
New
Increased
Reduced
Closed

Top Buys

1 +$117M
2 +$94.9M
3 +$85.6M
4
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$67.7M
5
JCI icon
Johnson Controls International
JCI
+$64.6M

Top Sells

1 +$450M
2 +$144M
3 +$124M
4
NVDA icon
NVIDIA
NVDA
+$97.8M
5
FBTC icon
Fidelity Wise Origin Bitcoin Fund
FBTC
+$96.7M

Sector Composition

1 Technology 13.38%
2 Industrials 11.13%
3 Consumer Discretionary 10.55%
4 Healthcare 8.01%
5 Financials 7.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMPH icon
2326
Amphastar Pharmaceuticals
AMPH
$1.17B
-42,614
AMWD icon
2327
American Woodmark
AMWD
$930M
-11,160
ANSCU
2328
Agriculture & Natural Solutions Acquisition Corp Unit
ANSCU
-91,834
AOSL icon
2329
Alpha and Omega Semiconductor
AOSL
$790M
-22,600
APGE icon
2330
Apogee Therapeutics
APGE
$3.65B
-70,766
API
2331
Agora
API
$298M
-270,035
APPF icon
2332
AppFolio
APPF
$9.36B
-3,310
ARGX icon
2333
argenx
ARGX
$51.2B
-5,368
ARIS
2334
DELISTED
Aris Water Solutions
ARIS
-17,300
ASTS icon
2335
AST SpaceMobile
ASTS
$19.4B
0
AU icon
2336
AngloGold Ashanti
AU
$32.1B
-18,116
AVDL
2337
Avadel Pharmaceuticals
AVDL
$1.84B
-47,644
AZZ icon
2338
AZZ Inc
AZZ
$3.01B
-4,870
BANF icon
2339
BancFirst
BANF
$3.63B
-4,538
BATRA icon
2340
Atlanta Braves Holdings Series A
BATRA
$2.69B
-12,000
BB icon
2341
BlackBerry
BB
$2.76B
-279,404
BCE icon
2342
BCE
BCE
$20.8B
-80,000
BCYC
2343
Bicycle Therapeutics
BCYC
$477M
-42,500
BEAM icon
2344
Beam Therapeutics
BEAM
$2.31B
-15,531
BEPC icon
2345
Brookfield Renewable
BEPC
$7.86B
-8,200
BHAT icon
2346
Blue Hat Interactive Entertainment Technology
BHAT
$52.8M
-735
BIIB icon
2347
Biogen
BIIB
$21.9B
-79,516
BILL icon
2348
BILL Holdings
BILL
$4.73B
-141,742
BITF
2349
Bitfarms
BITF
$2.12B
-295,822
BMY icon
2350
Bristol-Myers Squibb
BMY
$92.8B
-664,205